Marker | Age group | Men | Women | Total |
---|---|---|---|---|
N (%) | N (%) | N (%) | ||
MDRD | 65–69 | 26 (14.5) | 50 (29.1) | 76 (21.7) |
70–79 | 101 (27.5) | 105 (34.4) | 206 (30.6) | |
80+ | 128 (44.3) | 94 (59.5) | 222 (49.7) | |
Overall | 255 (30.5) | 249 (39.2) | 504 (34.3) | |
CKD-EPI | 65–69 | 21 (11.7) | 34 (19.8) | 55 (15.7) |
70–79 | 98 (26.6) | 90 (29.5) | 188 (27.9) | |
80+ | 146 (50.5) | 97 (61.4) | 243 (54.4) | |
Overall | 265 (31.7) | 221 (34.8) | 486 (33.0) | |
Cystatin-C based eGFR | 65–69 | 4 (2.2) | 7 (4.1) | 11 (3.1) |
70–79 | 30 (8.2) | 36 (11.8) | 66 (9.8) | |
80+ | 86 (29.8) | 51 (32.3) | 137 (30.7) | |
Overall | 120 (14.4) | 94 (14.8) | 214 (14.6) | |
Albumin creatinine ratio (ACR) > 30 mg/g | 65–69 | 17 (9.5) | 7 (4.1) | 24 (6.8) |
70–79 | 43 (11.7) | 12 (3.9) | 55 (8.2) | |
80+ | 49 (17.0) | 17 (10.8) | 66 (14.8) | |
Overall | 109 (13.0) | 36 (5.7) | 145 (9.9) |